Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ETON NASDAQ:IVA NASDAQ:NKTX NASDAQ:ORKA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$19.93+0.7%$17.47$6.37▼$23.00$534.48M1.16338,391 shs269,545 shsIVAInventiva$6.53+3.7%$4.90$1.60▼$6.55$624.67M0.6659,005 shs112,843 shsNKTXNkarta$2.13-2.7%$2.12$1.31▼$4.55$151.28M0.86699,183 shs732,625 shsORKAOruka Therapeutics$19.79+3.2%$15.41$5.49▼$31.13$741.16M-0.29492,635 shs284,481 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals0.00%-6.30%+11.53%+37.21%+235.52%IVAInventiva0.00%+7.93%+16.61%+113.40%+247.36%NKTXNkarta0.00%+4.41%0.00%+21.37%-48.92%ORKAOruka Therapeutics0.00%+30.20%+32.20%+57.13%-20.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeETONEton Pharmaceuticals$19.93+0.7%$17.47$6.37▼$23.00$534.48M1.16338,391 shs269,545 shsIVAInventiva$6.53+3.7%$4.90$1.60▼$6.55$624.67M0.6659,005 shs112,843 shsNKTXNkarta$2.13-2.7%$2.12$1.31▼$4.55$151.28M0.86699,183 shs732,625 shsORKAOruka Therapeutics$19.79+3.2%$15.41$5.49▼$31.13$741.16M-0.29492,635 shs284,481 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceETONEton Pharmaceuticals0.00%-6.30%+11.53%+37.21%+235.52%IVAInventiva0.00%+7.93%+16.61%+113.40%+247.36%NKTXNkarta0.00%+4.41%0.00%+21.37%-48.92%ORKAOruka Therapeutics0.00%+30.20%+32.20%+57.13%-20.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceETONEton Pharmaceuticals 2.50Moderate Buy$29.6748.85% UpsideIVAInventiva 2.63Moderate Buy$15.57138.46% UpsideNKTXNkarta 2.75Moderate Buy$13.60538.50% UpsideORKAOruka Therapeutics 2.83Moderate Buy$42.00112.23% UpsideCurrent Analyst Ratings BreakdownLatest NKTX, IVA, ETON, and ORKA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/30/2025IVAInventivaCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.009/29/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.009/27/2025ETONEton PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IVAInventivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NKTXNkartaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ORKAOruka TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/17/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $56.009/3/2025IVAInventivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.009/2/2025IVAInventivaGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $13.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.008/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookETONEton Pharmaceuticals$39.01M13.70N/AN/A$0.94 per share21.20IVAInventiva$9.95M62.78N/AN/A($1.21) per share-5.40NKTXNkartaN/AN/AN/AN/A$5.78 per shareN/AORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateETONEton Pharmaceuticals-$3.82M-$0.16N/A39.86N/A-7.10%-0.73%-0.22%11/11/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/AN/ANKTXNkarta-$108.79M-$1.48N/AN/AN/AN/A-27.74%-22.38%11/6/2025 (Estimated)ORKAOruka Therapeutics-$83.72M-$2.81N/AN/AN/AN/A-26.26%-24.16%11/12/2025 (Estimated)Latest NKTX, IVA, ETON, and ORKA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025NKTXNkarta-$0.37-$0.31+$0.06-$0.31N/AN/A8/11/2025Q1 2025ORKAOruka Therapeutics-$0.48-$0.46+$0.02-$0.46N/AN/A8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthETONEton PharmaceuticalsN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioETONEton Pharmaceuticals1.141.771.16IVAInventivaN/AN/AN/ANKTXNkartaN/A15.6715.67ORKAOruka TherapeuticsN/A27.4227.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipETONEton Pharmaceuticals27.86%IVAInventiva19.06%NKTXNkarta80.54%ORKAOruka Therapeutics56.44%Insider OwnershipCompanyInsider OwnershipETONEton Pharmaceuticals16.03%IVAInventiva32.00%NKTXNkarta8.40%ORKAOruka Therapeutics24.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableETONEton Pharmaceuticals2026.82 million22.52 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableNKTXNkarta14071.03 million65.06 millionOptionableORKAOruka TherapeuticsN/A37.45 million28.20 millionN/ANKTX, IVA, ETON, and ORKA HeadlinesRecent News About These CompaniesOruka Therapeutics files to sell 39.43M shares of common stock for holdersOctober 4 at 11:45 AM | msn.comBTIG Research Reiterates "Buy" Rating for Oruka Therapeutics (NASDAQ:ORKA)October 1, 2025 | americanbankingnews.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $42.00 Average PT from BrokeragesOctober 1, 2025 | americanbankingnews.comBTIG Reiterates Oruka Therapeutics (ORKA) Buy RecommendationSeptember 29, 2025 | msn.comLeerink sees greater opportunity for Oruka’s ORKA-002 after MoonLake newsSeptember 29, 2025 | msn.comOruka Therapeutics (NASDAQ:ORKA) Shares Gap Up - What's Next?September 29, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from BTIG ResearchSeptember 29, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Buy" from BrokeragesSeptember 28, 2025 | marketbeat.comQ3 EPS Forecast for Oruka Therapeutics Increased by AnalystSeptember 22, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Trading Down 6.2% - Here's What HappenedSeptember 20, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Upgraded at Wall Street ZenSeptember 20, 2025 | marketbeat.comOruka Therapeutics, Up 10%, Is Trying To Take On AbbVie's Biggest MoneymakerSeptember 19, 2025 | msn.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Expected to Rise, BTIG Research Analyst SaysSeptember 19, 2025 | marketbeat.comOruka Therapeutics presents positive interim phase 1 results for ORKA-001 at EADV CongressSeptember 18, 2025 | pharmabiz.comPOruka Therapeutics (NASDAQ:ORKA) Shares Gap Up - Still a Buy?September 18, 2025 | marketbeat.comOruka reveals $180M financing and late breaking psoriasis dataSeptember 18, 2025 | thepharmaletter.comTOruka Therapeutics stock surges after positive Phase 1 resultsSeptember 18, 2025 | za.investing.comOruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trialSeptember 18, 2025 | msn.comOruka Therapeutics, Up 9%, Is Trying To Take On AbbVie's Biggest MoneymakerSeptember 18, 2025 | msn.comOruka Therapeutics Stock (ORKA) Soars on New Psoriasis Drug That Could Challenge AbbVie (ABBV)September 18, 2025 | msn.comOruka Therapeutics Secures $180 Million in PIPE Financing to Advance Chronic Skin Disease TreatmentsSeptember 17, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025Is Qualcomm Tesla’s Next Rival in Autonomous Driving?By Sam Quirke | September 9, 2025NKTX, IVA, ETON, and ORKA Company DescriptionsEton Pharmaceuticals NASDAQ:ETON$19.93 +0.13 (+0.66%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$19.94 +0.01 (+0.05%) As of 10/3/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Inventiva NASDAQ:IVA$6.53 +0.23 (+3.65%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$6.59 +0.06 (+0.92%) As of 10/3/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Nkarta NASDAQ:NKTX$2.13 -0.06 (-2.74%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$2.14 +0.01 (+0.47%) As of 10/3/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Oruka Therapeutics NASDAQ:ORKA$19.79 +0.61 (+3.18%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$19.66 -0.13 (-0.66%) As of 10/3/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
